XML 31 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income/(Loss) Per Share
12 Months Ended
Dec. 31, 2022
Net Income/(Loss) Per Share  
Net Income/(Loss) Per Share

5.   Net Income/(Loss) Per Share

The following table sets forth the computation of basic and diluted net income/ (loss) per share for the years ended December 31, 2022 and 2021 (in thousands, except number of shares and per share amounts):

    

Year ended 

    

Year ended 

December 31, 

December 31, 

Numerator:

    

2022

    

2021

Net income/ (loss)

$

5,321

$

(51,112)

Net loss attributable to noncontrolling interest

 

21

 

247

Net income/ (loss) attributable to Vaccitech shareholders

$

5,342

$

(50,865)

Denominator:

 

  

 

  

Weighted-average ordinary shares outstanding, basic

 

37,248,126

 

25,894,375

Effect of dilutive stock options

921,181

Weighted-average ordinary shares outstanding, diluted

38,169,307

25,894,375

Net income/ (loss) per share attributable to ordinary shareholders, basic

$

0.14

$

(1.96)

Net income/ (loss) per share attributable to ordinary shareholders, diluted

$

0.14

$

(1.96)

Potential ordinary shares issuable for stock options that are excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact are as follows:

    

Year ended

    

Year ended

December 31, 

December 31, 

    

2022

    

2021

Stock options

 

2,912,756

 

2,604,969